Skip to main navigation
Innovating Solutions for Wound & Burn Care

Menu

Skip to content
  • Home
  • About Us
  • Products
  • Investor Relations
  • Contact Us

Investor Relations

NASDAQ: MDWD
featured-image-1

Press Releases

Date Title and Summary View
Toggle SummaryMay 5, 2014 MediWound Announces Extraordinary General Meeting of Shareholders View HTML
MediWound Announces Extraordinary General Meeting of Shareholders 15.9 KB
Toggle SummaryMay 2, 2014 MediWound Reports First Quarter 2014 Financial Results View HTML
MediWound Reports First Quarter 2014 Financial Results 35.4 KB
Toggle SummaryMarch 25, 2014 MediWound Announces Closing of Initial Public Offering View HTML
MediWound Announces Closing of Initial Public Offering 13.1 KB
Toggle SummaryMarch 20, 2014 MediWound Prices Initial Public Offering View HTML
MediWound Prices Initial Public Offering 11.5 KB
Toggle SummarySeptember 23, 2012 Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug – NexoBrid™
NexoBrid™ has shown statistically significant effect in earlier eschar removal from burn wounds and reduction in the number and extent of surgical excision and autografting
View HTML
Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug – NexoBrid™ 13.9 KB

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 15
  • Page 16
  • Page 17
  • Current page 18
Displaying 171 - 175 of 175 results

Investor Relations

  • Press Releases
  • In The News
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Analyst Coverage
  • Investor FAQs
  • Contact Us

Shareholder Tools

  • Printed Materials
  • Email
  • Print
 
Copyright © 2021, MediWound. All rights reserved. Terms of Use | Privacy Policy